Search Results

Containing any of the words

Only of the type

Recommendations for the safe and effective use of Acellular Dermal Matrix in Breast Reconstruction Medical Report

The SFDA Grants Breakthrough Designation to "ZENBEXUS" for the Treatment of Adult Patients with Multiple Myeloma News

In a Meeting with ‘Alternative Breast Milk Companies’ SFDA declares: ‘Milk Packs for Infants Under 3 Years of Age Will be Subject to Pricing’ News

The SFDA Website Contains more than 2000 Educational and Informational Subject:It Completes its Second Year with Noticeable Progress News

An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease Drug Clinical Trial

"Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy" Drug Clinical Trial

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease Drug Clinical Trial

An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension Drug Clinical Trial

An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension Drug Clinical Trial

An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension Drug Clinical Trial